Dizal Pharma

NEWS & INSIGHTS (incl. Key Themes, Latest Interviews, Recent Reg. Guidance)

• Notable Theme (Commercial): The seemingly insatiable appetite for drugs to treat metabolic diseases, which has seen China emerge as a key source of new R&D candidates, looks set to propel Eli Lilly and Novo Nordisk to become the world's largest pharma companies within the next five years.
• Notable Theme (Commercial): Japan continued to cut drug reimbursement prices via multiple mechanisms, including cost-effectiveness assessments for selected products, which most recently will lead to a 15% price cut for Alzheimer's therapy Leqembi.
• Notable Theme (Regulatory): European Medicines Agency's attempt to adopt a US-style "assessment aid" approach, where sponsors pre-fill regulatory templates, has not delivered the expected benefits in the EU.

EDITORIAL CONTENTS (incl. Podcasts, Webinars)

• Notable Podcast: Drug Fix: US FDA Changes COVID-19 Vaccine Labeling, Reimbursement Confusion Rises
• Notable Webinar: AI Won’t Replace You—But Clinical Teams Using It Might (September 24, 2025)
• Notable Webinar: How is China Shaping the Face of the Pharma Industry? (September 30, 2025)

DEALS & FINANCING (incl. M&As, Licensing, Financing)

• Notable M&A: Terumo to Pay $1.5B to Buy OrganOx
• Notable Licensing: BioArctic and Novartis Sign an Option, Collaboration and License Agreement using BrainTransporter Technology totalling $2B
• Notable Financing: Strand Therapeutics Gets $153M in Series B Financing

KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)

• Notable Analysis: IO Biotech | Cylembio | Melanoma (Phase 3): “Despite missing PFS mark, Cylembio combination shows clinical benefits over Keytruda alone in frontline metastatic melanoma…”
• Notable Analysis: Pfizer | Inclacumab | Sickle Cell Disease (Phase 3): “Pfizer’s inclacumab becomes second monoclonal antibody targeting P-selectin to fail Phase III trial in SCD…”
• Notable Analysis: Regeneron | Cemdisiran | Myasthenia Gravis (Phase 3): “Cemdisiran, an RNA interference therapy, emerges as a low-burden C5 inhibitor with competitive efficacy in gMG…”

RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)

• Notable Report: Commercialization Countdown: Step-by-Step Instructions for Acing Your Product Launch
• Notable Report: Q2 Round Up: You Can’t Always Get What You Want
• Notable Report: Gene, Cell, & RNA Therapy Landscape Q2 2025
• Notable Report: Disease Analysis: Pancreatic Cancer
• Notable Report: Disease Analysis: Sickle Cell Disease
• Notable Report: Patient-based Forecast: Chronic Urticaria
• Notable Report: Robotic-Assisted Surgical Systems
• Notable Report: Anemia of CKD KOL Interview - US, Northeast #1
• Notable Report: Diabetic Nephropathy (DN) KOL Interview - UK
• Notable Report: Pancreatic Cancer KOL Interview - US, East

Note: Require research support on scientific meetings not under below list? Submit your inquiry via Ask the Analyst!

Trialtrove分析师团队每年审阅全球160+医学年会的数千篇摘要披露，并在经过数据审核后将相关信息收录于数据库，其中包括：临床数据披露、临床方案更新、项目状态、入组进度等信息。下列表格为2021年至今全球各大领域重要医学会议的检索链接，以便快速找到有在某会议中披露最新动态的临床试验。

注：若想查阅未在下列范围内的医学会议，欢迎使用Ask the Analyst服务寻求辅助。